NCT00123279已完成2 期
A Dose-escalation Clinical Trial of Intravitreal Microplasmin in Patients Undergoing Surgical Vitrectomy for Vitreomacular Traction Maculopathy
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 3
- 主要终点
- Grade of Posterior Vitreous Detachment (PVD) preoperatively and release of vitreomacular traction
研究概览
简要总结
The purpose of this trial is to evaluate the safety and preliminary efficacy of different doses and several exposure times of intravitreal microplasmin in the setting of pars plana vitrectomy for vitreomacular traction maculopathy.
详细描述
Study drug will be administered in the mid-vitreous by injection. Patients will be enrolled into the cohorts in a sequential dose/time-escalating fashion. To ensure that enrolment is evenly balanced across eligible conditions, enrolment of any specific underlying disease type into any cohort will be capped at five (5) patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with vitreomacular traction maculopathy for whom vitrectomy is indicated, according to the principal investigator, including:
- •Macular edema associated with vitreomacular traction (DME, VMTS);
- •Stage II-III macular hole of < 6 months duration since symptom onset;
- •Demonstration of vitreomacular adhesion (based on preoperative optic coherence tomography [OCT]) in the study eye;
- •OCT - presence of posterior hyaloid membrane inserting on to the macula, but with some area of clear separation visible between the retina and the posterior hyaloid.
排除标准
- •Evidence of fibrocellular proliferation characterized by whitish epimacular tissue (surface wrinkling is not an exclusion criterion).
- •Patients with vitreous hemorrhage which precludes either of the following: visualization of the posterior pole by visual inspection OR adequate assessment of the macula by either OCT and/or fluorescein angiogram in the study eye.
- •Patients with rhegmatogenous retinal detachment, proliferative vitreoretinopathy (PVR), or retinal degenerative changes in the study eye.
- •Patients with high myopia or aphakia in the study eye
- •Patients with history of rhegmatogenous retinal detachment in the fellow eye or family history of retinal detachment
- •Patients who are considered likely to require intraocular surgery in the study eye for any reason other than vitreomacular traction maculopathy/macular edema in the coming three months.
- •Patients who have had ocular surgery in the study eye in the prior three months.
- •Patients who have had a vitrectomy in the study eye at any time.
- •Patients with a history of uveitis or significant trauma in the study eye.
- •Patients who are currently being treated for glaucoma in the study eye.
- •Patients who have had laser photocoagulation treatment in the study eye in the previous 3 months.
- •Intravitreal injection of any drug in the study eye in the previous 6 months or during the study.
- •Patients who are pregnant or of child-bearing potential not utilizing a form of contraception acceptable to the investigator.
- •Patients who, in the investigator's view, will not complete all visits and investigations, including the exit visit at 6 months.
- •Patients who have participated in an investigational drug study within the past 30 days.
- •HgA1c > 9%.
- •Patients with hypertension (either systolic blood pressure [SBP] > 170 or diastolic blood pressure [DBP] > 100 mm Hg).
- •Patients with a life-expectancy less than 6 months.
- •Patients who have previously participated in this trial.
研究组 & 干预措施
2
Experimental
干预措施: Microplasmin (Drug)
1
Experimental
干预措施: Microplasmin (Drug)
3
Experimental
干预措施: Microplasmin (Drug)
4
Experimental
干预措施: Microplasmin (Drug)
5
Experimental
干预措施: Microplasmin (Drug)
6
Experimental
干预措施: Microplasmin (Drug)
结局指标
主要结局
Grade of Posterior Vitreous Detachment (PVD) preoperatively and release of vitreomacular traction
时间窗: Baseline, 1,2 and 3hr, 1, 3, 14, 28, 90 and 180 Days
次要结局
- The occurrence of any (serious) adverse event(Throught-out the study)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
1 期
A Dose Escalation Trial of an Intravitreal Injection of Sirna-027 in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)Age-Related Macular DegenerationChoroidal NeovascularizationNCT00363714Allergan26
已完成
1 期
Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravitreal vMCO-I in Patients With Advanced Retinitis PigmentosaRetinitis PigmentosaRetinal DiseasesRetinal DegenerationNCT04919473Nanoscope Therapeutics Inc.11
暂停
1 期
Evaluation of IBI302 Injection in nAMD or DMENeovascular Age-related Macular DegenerationDiabetic Macular EdemaNCT05961007Innovent Biologics (Suzhou) Co. Ltd.234
已完成
1 期
Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)Neovascular Age-Related Macular DegenerationDiabetic Macular EdemaNCT01997164Regeneron Pharmaceuticals20
已完成
2 期
Prospective, Randomized, Multicenter, Open Label, Phase II Study to Access Efficacy and Safety of Lucentis® Monotherapy Compared With Lucentis® Plus Panretinal Photocoagulation (PRP) and PRP in the Treatment of Patients With High Risk Proliferative Diabetic RetinopathyHigh Risk Proliferative Diabetic RetinopathyNCT01280929José Cunha-Vaz54